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The  recent  boom  in  genome-wide  association  (GWA) 
studies has resulted in a vast expansion of our knowledge 
of common variants influencing human diseases. So far, 
1,888 single nucleotide polymorphism (SNP) associations 
have been reported, 1,435 of which are unique to the SNP 
[1]. Neurological diseases are underrepresented among 
successful GWA study findings. They account for only 36 
publications, reporting 63 unique SNPs, out of a total of 
812 publications and 3,942 unique SNPs [1]. If we exclude 
the  APOE  locus  and  the  HLA  region  of  chromosome 
6p21 (which are associated with multiple diseases), the 
number  of  unique  significant  neurological  loci  found 
drops to 42.
A probable explanation for the underrepresentation is 
the cost and difficulty of obtaining large sample sets; for 
anthropomorphic  traits  such  as  height  and  readily 
quantifiable measures such as blood lipids, sample sizes 
of up to 100,000 have been analyzed in widely successful 
GWA  studies.  A  further  complication  in  neurological 
diseases  is  the  complexity  of  phenotyping  brain 
phenotypes (description-based only, as in migraine), and 
the  myriad  diagnostic  divisions  (as  in  epilepsy),  which 
together make collecting sufficiently large samples of any 
given  subtype  a  hard  task.  Estimates  from  several 
diseases suggest that sample sizes exceeding 10,000 are 
required  to  reach  sufficient  statistical  power  to  detect 
new loci [2].
Gene loci predisposing to migraine
The recent publication of the large-scale GWA study by 
the International Headache Genetics Consortium [3] in 
Nature Genetics was the first GWA study reported for a 
headache  disorder.  As  the  primary  finding,  it  reported 
the first genome-wide significant association in the group 
of  paroxysmal  neurological  diseases,  which  comprises 
epilepsy, migraine, episodic ataxia and various cerebro-
vascular and sleep disorders. In this study [3], a total of 
5,933 cases and 50,809 controls were used to establish a 
single significant locus. The discovery sample consisted 
of  2,731  migraine  cases  collected  from  four  European 
head  ache centers located in three countries. The initial 
finding was replicated in 3,202 cases and 40,062 indepen-
dent controls from four European countries. Using RNA 
expression data from lymphoblastoid cell lines, the iden-
ti  fied variant rs1835740 was found to be an expression 
quantitative locus (eQTL) affecting glutamate metabo  lism. 
As glutamate is a major excitatory neurotransmitter in 
the  central  nervous  system  (CNS),  the  eQTL  finding 
provides a promising link between the genetic association 
and  function.  The  eQTL  data  suggest  that  the  pre-
disposing allele of rs1835740 stimulates the expression of 
metadherin  (MTDH,  also  called  astrocyte  elevated 
gene-1, AEG-1), which downregulates excitatory amino-
acid transporter 2 (EAAT2, also called glutamate trans-
porter 1, GLT-1), the main glutamate transporter in the 
brain. This finding stimulates the hypothesis that accu-
mu  lation of glutamate, a potent neurotransmitter, in the 
synaptic cleft might contribute to the occurrence of the 
migraine attack.
A  problem  in  uncovering  the  genetic  component  of 
migraine  has  been  the  dearth  of  unambiguous  results. 
After  the  early  encouraging  findings  of  the  mutations 
causing the rare Mendelian forms of migraine (familial 
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first linkage scan for common migraine [4], progress has 
been slow. The genes identified in FHM, similar to the 
corresponding  findings  for  epilepsy,  pinpointed  ion 
channel defects, grouping these diseases into channelo-
pathies. However, neither targeted ion channel associa-
tion studies [5] nor the first GWA studies have provided 
evidence of the involvement of common variants in ion 
channel genes in common forms of migraine or epilepsy 
[3,6].  Candidate  gene  studies  covering  obvious  targets 
(the  ion  channels  and  the  estrogen  system)  and  up  to 
1,000 migraine cases and controls turned up conflicting 
results  at  best  [4].  Although  a  number  of  loci  using 
family-based linkage studies were identified, no genes for 
the  common  forms  were  found.  Thus,  the  genetic  and 
functional  link  between  FHM  and  common  forms  of 
migraine remained unclear.
Interestingly, the GWA association and the eQTL data 
point to the same synaptic transmission mechanism (the 
imbalance in glutamate release and its clearance from the 
synaptic  cleft)  that  has  been  shown  to  be  a  key 
component of FHM pathogenesis in migraine with aura 
(Figure 1), although through a more peripheral part of 
the pathway in the latter [3]. Although this provides a 
potential  link  between  FHM  and  common  migraine 
pathophysiology, it should be noted that because of the 
ascertainment  of  the  GWA  study  cases  from  tertiary 
headache clinics, it is not possible to estimate the effect 
of the identified variant on a population level from the 
current  data.  What  we  can  conclude  is  that  among 
patients whose migraine is severe enough to need tertiary 
care,  this  variant  is  significantly  overrepresented. 
Further  more, mutations in the gene encoding the EAAT1 
transporter also result in an episodic disease phenotype 
[7]. The diversity of pathways resulting in similar synaptic 
events  might  reflect  one  of  the  challenges  we  might 
encounter  in  dissecting  the  genetic  predisposition  of 
paroxysmal CNS disorders.
Does the clinical classification facilitate gene 
identification?
The obvious next steps for GWA studies are to address 
different  migraine  subtypes  (such  as  migraine  without 
aura)  and  from  different  recruitment  settings  (such  as 
population-based, instead of clinic based migraine cases). 
As  mentioned  above,  many  neurological  diseases  lack 
such  easily  quantifiable  phenotypes  as  serum  lipid  or 
blood sugar levels that are available elsewhere. The lack 
of quantitative phenotypes is also reflected in dissecting 
the umbrella diagnosis into subphenotypes, as they may 
similarly  be  based  on  non-objective  measures.  Thus, 
there  is  a  chance  that  clinical  subtypes  might  be  of 
limited help and traditional diagnostic boundaries might 
not  correlate  with  identified  susceptibility  genes. 
Although  data  are  limited,  there  is  emerging  evidence 
that  susceptibility  loci  can  cross  diagnostic  boundaries 
and be associated with multiple traits, such as schizo-
phrenia and bipolar disorder [8]. There are similar over-
laps with many autoimmune diseases and immunolo  gi-
cally mediated traits [9]. There is evidence that the same 
locus  or  even  same  variant  can  contribute  to  the 
susceptibility of different disease outcomes.
A case in point is that in another major paroxysmal 
CNS  disorder,  epilepsy,  there  is  a  long  tradition  of 
rigorous  clinical  subgrouping.  If  secondary  factors 
contribute to the precise form of the disease, such strong 
divisions might distort from the ultimate goal of identi-
fication of the biological basis of seizure susceptibility, as 
was discussed in a recent editorial [10]. In the case of 
migraine,  the  diagnostic  classification  is  perhaps  more 
dynamic than for epilepsies. The classification recognizes 
that most patients suffer from various different forms of 
attacks, such as a combination of migraine attacks with 
and  without  aura.  A  migraine  patient  may,  over  the 
course  of  decades,  pass  through  different  types  of 
migraine.  Diagnostic  flexibility  accounts  better  for  the 
varying  severity  spectrum  both  between  patients  and 
along a timeline. Although this flexibility does not abolish 
the phenotyping challenges, it is likely to be helpful in 
large  GWA  meta-analyses.  When  subsequent  migraine 
association studies have identified more loci and we start 
to  tackle  their  interplay  in  disease  susceptibility,  this 
might provide us with new tools for disease classification.
It  should  perhaps  not  be  surprising  that  a  highly 
adaptable  system  such  as  the  brain,  with  its  myriad, 
cross-compensating  pathways,  can  react  with  a  very 
limited set of overt phenotypes, such as headache, to a 
variety of biological challenges. Therefore, summing over 
all possible symptom backgrounds in a large-scale GWA 
study is likely to result in only small odds ratios and thus 
sample  sizes  exceeding  10,000  may  well  be  necessary. 
These large samples should also allow secondary analyses 
addressing questions related to disease subclassification 
and co-morbidity.
Conclusions
The first genetic link to common forms of migraine was 
recently reported, pointing the way towards alterations in 
glutamate homeostasis. This finding is the first step to 
uncovering  the  genetic  background.  Upcoming  larger 
migraine  GWA  studies,  across  different  ascertainment 
schemes, are likely to identify more genes and cellular 
pathways contributing to migraine susceptibility and will 
hopefully  also  shed  light  on  the  potentially  different 
genetic background of different migraine subtypes. The 
emerging wealth of GWA data from other neurological 
and neuropsychiatric traits will also provide an oppor-
tunity to study whether some loci or pathways contribute 
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genetic data will cross traditional diagnostic boundaries. 
However,  it  is  evident  that  not  all  of  genetic  pre  dis-
position  is  explained  by  common  variants,  and  future 
exome  and  whole-genome  sequencing  studies  in  large 
datasets will probably identify contributing highly pene-
trant low-frequency variants and expand our knowledge 
of the migraine susceptibility landscape.
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Figure 1. Localization and effect of a variant identified in the recent genome-wide association study of migraine in synaptic transmission, 
together with the previously known mutations in familial hemiplegic migraine (FHM: genes are FHM1, CACNA1A; FHM2, ATP1A2; 
FHM3, SCN1A). The asterisk indicates the excitatory amino acid transporter 2 (EAAT2/GLT-1) recently linked to migraine. Glu, glutamate; FHM1-3, 
products of genes reported for familial hemiplegic migraine; mGluR, metabolic glutamate receptor. Black dots indicate the accumulation of the 
neurotransmitter glutamate in the synaptic cleft.
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